Literature DB >> 7721861

Expression, refolding, and autocatalytic proteolytic processing of the interleukin-1 beta-converting enzyme precursor.

P Ramage1, D Cheneval, M Chvei, P Graff, R Hemmig, R Heng, H P Kocher, A Mackenzie, K Memmert, L Revesz.   

Abstract

The interleukin-1 beta-converting enzyme is a heterodimeric cysteine protease that is produced as a 45-kDa precursor. The full-length precursor form of the enzyme was expressed in Escherichia coli as insoluble inclusion bodies. Following solubilization and refolding of the 45-kDa protein, autoproteolytic conversion to a heterodimeric form containing 10- and 20-kDa subunits was observed. This enzyme had catalytic activity against both natural (interleukin-1 beta precursor) and synthetic peptide substrates. The inclusion of a specific inhibitor (SDZ 223-941) of the converting enzyme in the refolding mixture prevented proteolytic processing to the 10-/20-kDa form. Similarly, refolding under nonreducing conditions also prevented processing. Time course experiments showed that the 10-kDa subunit was released from the 45-kDa precursor before the 20-kDa subunit, implying that the N-terminal portion of the precursor is released last and may play a regulatory role.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721861     DOI: 10.1074/jbc.270.16.9378

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

Review 2.  Current knowledge on procaspase-1 variants with reduced or abrogated enzymatic activity in autoinflammatory disease.

Authors:  Hella Luksch; Stefan Winkler; Michael C Heymann; Felix Schulze; Sigrun R Hofmann; Joachim Roesler; Angela Rösen-Wolff
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

3.  Cytomegalovirus assemblin: the amino and carboxyl domains of the proteinase form active enzyme when separately cloned and coexpressed in eukaryotic cells.

Authors:  M R Hall; W Gibson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 4.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 5.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

6.  Decreased retinal neuronal cell death in caspase-1 knockout mice.

Authors:  Jun Arai; Naomichi Katai; Keisuke Kuida; Takanobu Kikuchi; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.447

Review 7.  Proteases for cell suicide: functions and regulation of caspases.

Authors:  H Y Chang; X Yang
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

8.  Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases.

Authors:  S M Srinivasula; M Ahmad; T Fernandes-Alnemri; G Litwack; E S Alnemri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 9.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Authors:  Rumani Singh; Anthony Letai; Kristopher Sarosiek
Journal:  Nat Rev Mol Cell Biol       Date:  2019-03       Impact factor: 94.444

10.  Caspase-2 (Nedd-2) processing and death of trophic factor-deprived PC12 cells and sympathetic neurons occur independently of caspase-3 (CPP32)-like activity.

Authors:  L Stefanis; C M Troy; H Qi; M L Shelanski; L A Greene
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.